Headquarters: 777 Old Saw Mill River Road
Tarrytown, NY 10591
CEO: Leonard Schleifer, M.D.
Stock Symbol: REGN
Regeneron is a leading science-based biopharmaceutical company that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions.
Regeneron commercializes medicines for eye diseases, high LDL cholesterol and a rare inflammatory condition and has
product candidates in development in other areas of high unmet medical need, including rheumatoid arthritis, asthma,
atopic dermatitis, pain, cancer, and infectious diseases.
The company's main products are EYLEA, Arcalyst and Zaltrap.
Corporate offices are based in Tarrytown, NY with manufacturing facility in Rensselaer, NY.
In 2015, Regeneron reported total revenues of $4.15 billion, up 46% from the previous year, and net income of $338 million. The company spent $1.271 billion for research and development in 2014.
For 2015, net sales of EYLEA in the United States increased 54% to $2.676 billion.
The company has partnered with French pharmaceutical giant Sanofi to develop Dupilumab, for treatment of adults with atopic dermatitis.
In 2015, PRALUENT (alirocumab) Injection became the first approved PCSK9 inhibitor in the U.S.
"Regeneron had a successful 2015, with strong growth in EYLEA sales for retinal diseases, the approval of Praluent for hypercholesterolemia, and important advances across all stages of our pipeline," said Leonard Schleifer, M.D., Ph.D., President and Chief Executive Officer of Regeneron. "In 2016, we look forward to driving increased physician education, patient access, and reimbursement for Praluent in the United States and to launching this important medicine in other countries around the world. We also anticipate significant pipeline progress including the U.S. FDA action on the sarilumab application for rheumatoid arthritis, the Phase 3 results and potential U.S. regulatory submission for dupilumab in atopic dermatitis, and the continued progress of our development programs for retinal diseases, asthma, pain, infectious diseases, and cancer. Realizing these important product and pipeline opportunities will require significant investments, which are essential to support our long-term growth and success."
Leonard Schleifer, M.D., Ph.D., a young neurologist and assistant professor at Cornell University Medical College, establishes the company in 1988 based on the principle that dedication to strong science would lead to important new medicines. His two co-founders are nationally-known scientists Drs. Alfred Gilman, Len's Ph.D. thesis advisor at the University of Virginia, and Dr. Eric Shooter. Drs. Gilman and Shooter recruit other leading scientists to join the company s scientific advisory board to help guide the young company. The company is named Regeneron because of the intention to focus on the use of gene technology to regenerate neurons. The first $1 million is raised from Merrill Lynch Venture Capital, Inc.
The company went public on Nasdaq stock market in 1991.
In 2011, Regeneron files for regulatory approval of EYLEA (aflibercept) Injection in February, receives FDA approval in November, and immediately makes the drug available in the U.S.
In 2012, FDA approves ZALTRAP for metastatic colorectal cancer.